Your session is about to expire
What is Valchlor
MechlorethamineThe Generic name of this drug
Treatment SummaryMechlorethamine is an alkylating drug used to treat Hodgkin’s disease and lymphomas. It is a very strong irritant that can damage mucous membranes and cause severe gastrointestinal and bone marrow damage. The FDA approved Valchlor (mechlorethamine) gel in 2013 as an orphan drug to treat stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have already received skin-directed therapy. Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% of mechlorethamine hydrochlor
Mustargenis the brand name
Valchlor Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mustargen
Mechlorethamine
1949
5
Effectiveness
How Valchlor Affects PatientsMechlorethamine, sometimes known as mustine, nitrogen mustard, or HN2, is a drug used to treat cancer. It was originally developed from the research done on toxic gases used in warfare. It works by disrupting the DNA of the cancer cells and causing them to die.
How Valchlor works in the bodyAlkylating agents work by preventing DNA from being copied, transcribed, and separated. They do this by attaching groups to the DNA, forming cross-links, or inducing mispairing of DNA bases. Mechlorethamine specifically targets all phases of the cell cycle.
When to interrupt dosage
The endorsed measure of Valchlor is contingent upon the determined condition, including Polycythemia Vera (PV), Mycosis Fungoides (MF) and Stage I Mycosis Fungoides. The amount of dosage can be found in the table below, relative to the technique of delivery (e.g. Powder, for solution - Intracavitary; Intravenous or Intravenous).Condition
Dosage
Administration
Mycosis Fungoides (MF)
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Gel, Gel - Topical, Topical, Intracavitary; Intravenous, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Cutaneous, Gel - Cutaneous
Chronic Lymphocytic Leukemia
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Gel, Gel - Topical, Topical, Intracavitary; Intravenous, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Cutaneous, Gel - Cutaneous
malignant effusion
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Gel, Gel - Topical, Topical, Intracavitary; Intravenous, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Cutaneous, Gel - Cutaneous
Hodgkin Disease
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Gel, Gel - Topical, Topical, Intracavitary; Intravenous, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Cutaneous, Gel - Cutaneous
Stage I Mycosis Fungoides
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Gel, Gel - Topical, Topical, Intracavitary; Intravenous, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Cutaneous, Gel - Cutaneous
Carcinoma, Bronchogenic
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Gel, Gel - Topical, Topical, Intracavitary; Intravenous, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Cutaneous, Gel - Cutaneous
Lymphoma
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Gel, Gel - Topical, Topical, Intracavitary; Intravenous, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Cutaneous, Gel - Cutaneous
Polycythemia Vera (PV)
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Gel, Gel - Topical, Topical, Intracavitary; Intravenous, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Cutaneous, Gel - Cutaneous
Warnings
Valchlor has two contraindications, so it should not be administered in conjunction with the conditions specified in the following table.Valchlor ContraindicationsCondition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Infectious Diseases
Do Not Combine
Common Valchlor Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Acteoside.
Valchlor Toxicity & Overdose RiskToo much exposure to the drug can cause serious decreases in white blood cells, red blood cells, and platelets, leading to difficulties with bleeding. Other common side effects include skin inflammation, itching, bacterial skin infection, ulcers or blisters, and darkening of the skin. The lowest toxic dose for a rat is 10mg/kg.
Valchlor Novel Uses: Which Conditions Have a Clinical Trial Featuring Valchlor?
Currently, 177 active clinical trials are being conducted to assess the efficacy of Valchlor in alleviating symptoms of malignant effusions, Stage I Mycosis Fungoides and Mycosis Fungoides (MF).Condition
Clinical Trials
Trial Phases
Polycythemia Vera (PV)
0 Actively Recruiting
Chronic Lymphocytic Leukemia
164 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3
malignant effusion
0 Actively Recruiting
Mycosis Fungoides (MF)
0 Actively Recruiting
Stage I Mycosis Fungoides
0 Actively Recruiting
Lymphoma
0 Actively Recruiting
Hodgkin Disease
4 Actively Recruiting
Not Applicable, Phase 1
Carcinoma, Bronchogenic
3 Actively Recruiting
Phase 3, Phase 1, Phase 2
Valchlor Reviews: What are patients saying about Valchlor?
2.7Patient Review
1/29/2018 This medication caused my skin to become severely irritated, and eventually led to a nasty infection. Even after the initial infection had healed, continuing treatment led to more severe irritation. Lowering the dosage helped somewhat, but even one dose causes inflammation and burning.
Patient Q&A Section about valchlor
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Valchlor chemotherapy?
"The cancer chemotherapy drug mechlorethamine was originally developed to be used intravenously, but it is safe and effective when used topically in the form of Valchlor for early stage CTCL."
Answered by AI
How much does Valchlor cost?
"The price of Valchlor topical gel 0.016% is approximately $5,502 for a supply of 60 grams, depending on the pharmacy you visit. This price is only for customers who pay in cash, and does not apply to those with insurance plans."
Answered by AI
How long does it take for Valchlor to work?
"After VALCHLOR is applied, it is absorbed into the skin and begins attacking cancerous lymphoma cells. The amount of time it takes for the medication to work can vary from person to person. Some people who responded to treatment saw results as early as 1 month, while others took up to 11 months."
Answered by AI